| Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025 WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ended March 31, 2025, and provided an update on its clinical development pipeline and other corporate developments. |
globenewswire.com |
2025-05-06 20:05:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics to Participate in Citizens Life Sciences Conference |
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025. |
globenewswire.com |
2025-05-01 11:30:00 |
Czytaj oryginał (ang.) |
| Prelude Announces Presentations at 2025 AACR Annual Meeting |
Preclinical data elucidating the mechanism of action of PRT3789, Prelude's first-in-class, highly selective SMARCA2 degrader currently in early clinical development |
globenewswire.com |
2025-04-25 20:05:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know |
Prelude Therapeutics (PRLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-10 17:01:06 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 |
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung (NSCLC), gastric and esophageal cancer |
globenewswire.com |
2025-03-10 09:30:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference |
WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025. |
globenewswire.com |
2025-03-05 09:30:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies |
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy |
globenewswire.com |
2024-12-11 09:30:00 |
Czytaj oryginał (ang.) |
| After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD) |
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-11-27 12:36:21 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit |
WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024. |
globenewswire.com |
2024-11-27 09:30:00 |
Czytaj oryginał (ang.) |
| Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) |
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-11-11 12:35:20 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium |
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) |
globenewswire.com |
2024-10-24 11:30:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium |
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) |
globenewswire.com |
2024-10-09 11:30:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial |
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation |
globenewswire.com |
2024-09-13 14:00:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 |
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) |
globenewswire.com |
2024-09-09 11:30:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September |
globenewswire.com |
2024-08-12 11:01:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers |
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms . |
globenewswire.com |
2024-07-09 11:30:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics to Participate in Upcoming Healthcare Conferences |
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. |
globenewswire.com |
2024-06-03 11:01:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference |
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14. |
globenewswire.com |
2024-05-09 11:01:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update |
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 |
globenewswire.com |
2024-05-07 11:01:00 |
Czytaj oryginał (ang.) |
| Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting |
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses |
globenewswire.com |
2024-04-09 20:35:00 |
Czytaj oryginał (ang.) |
| Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting |
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company's highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024. |
globenewswire.com |
2024-03-05 18:45:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics to Participate in Barclays Global Healthcare Conference |
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024. |
globenewswire.com |
2024-02-29 18:05:00 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 |
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 |
globenewswire.com |
2024-02-15 18:05:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 25th |
S, ASAN, PRLD, EMKR and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023. |
zacks.com |
2024-01-25 09:41:08 |
Czytaj oryginał (ang.) |
| Prelude Therapeutics Announces $25 Million Private Placement |
WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily fund the continued advancement of its SMARCA2 portfolio, for working capital and general corporate purposes. |
globenewswire.com |
2023-12-11 11:34:00 |
Czytaj oryginał (ang.) |
| Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results |
Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs with first program being a SMARCA degrader-antibody conjugate Cash runway into 2026 with $230.5 million of cash, cash equivalents and marketable securities WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results. |
globenewswire.com |
2023-11-01 18:10:00 |
Czytaj oryginał (ang.) |